药业公司将从2026年5月开始为移植患者提供lettermovir抗病毒药物. Pharmac to fund letermovir antiviral for transplant patients starting May 2026.

药业将从2026年5月开始资助抗病毒莱特莫维尔,以预防免疫系统疲软的患者感染细胞巨乳病毒,特别是那些正在接受干细胞移植后恢复过来的病人. Pharmac will fund the antiviral letermovir starting May 2026 to prevent cytomegalovirus infections in patients with weakened immune systems, particularly those recovering from stem cell transplants. 药物阻止病毒的重新激活,减少住院时间和并发症. The medication blocks virus reactivation, reducing hospital stays and complications. 药物以平板形式提供,预计在第一年将帮助大约90名患者,并得到医疗专业人员和病人团体的支持. Available in tablet form, it is expected to help roughly 90 patients in the first year and follows support from healthcare professionals and patient groups.